Replies to post #202486 on Biotech Values

[DFRAI]

ziop CAR program

I think this works to explain their CD19 program - they dont want to pursue a me too program and what to hit different targets - two targets taken by Merck (progress very well)

http://ziopharm.com/content/02-pipeline/03-presentations-publications/5-american-society-of-hematology-annual-meeting/1-pre-emptive-infusion-with-cd19-directed-car-modified-t-cells-infused-after-autologous-or-allogeneic-hematopoietic-cell-transplantation-for-patients-with-advanced-cd19-malignancies/20151207_ash_lc_jm.pdf


http://www.nature.com/articles/srep27130
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies w/ LJN Cooper co-author of

[CHM_760]

Yes, that's a good point. ZIOP's CAR-T trials for MerckKGa are not yet in the clinic, but will also utilize Rheoswitch technology.